Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $442000.0.

  • Stoke Therapeutics' Depreciation & Amortization (CF) fell 1814.81% to $442000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 1699.91%. This contributed to the annual value of $2.2 million for FY2024, which is 1200.0% down from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Depreciation & Amortization (CF) is $442000.0, which was down 1814.81% from $446000.0 recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $655000.0 for Q4 2023, and its period low was $247000.0 during Q1 2022.
  • For the 4-year period, Stoke Therapeutics' Depreciation & Amortization (CF) averaged around $507400.0, with its median value being $548000.0 (2024).
  • In the last 5 years, Stoke Therapeutics' Depreciation & Amortization (CF) skyrocketed by 14170.04% in 2023 and then plummeted by 1861.31% in 2025.
  • Stoke Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $609000.0 in 2022, then rose by 7.55% to $655000.0 in 2023, then fell by 16.18% to $549000.0 in 2024, then dropped by 19.49% to $442000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $442000.0 in Q3 2025, compared to $446000.0 in Q2 2025 and $477000.0 in Q1 2025.